Group 1 - The National Public Health and Medical Health Index (980016) increased by 0.86% as of August 15, 2025, with notable gains in constituent stocks such as Zhenhua Cell (688520) up 7.38% and BGI Genomics (688114) up 4.59% [1] - The Medical Health ETF Taikang (159760) rose by 1.23%, with a latest price of 0.66 yuan, and achieved an annualized return of 5.26% over the past three months [1] - CITIC Securities believes that the CXO industry is showing signs of a turning point, with valuation recovery expected to lead to a new development phase, following a period of adjustment due to a cooling investment environment and high base effects from COVID-19 orders [1] Group 2 - As of July 31, 2025, the top ten weighted stocks in the National Public Health and Medical Health Index accounted for 53.05% of the index, including WuXi AppTec (603259) and Hengrui Medicine (600276) [2] - The Medical Health ETF Taikang closely tracks the National Public Health and Medical Health Index, reflecting the market performance of publicly listed companies in the public health and medical health industry in the A-share market [2]
医疗健康ETF泰康(159760)今日涨超1.2%，CXO行业拐点显现，有望进入新一轮发展阶段
Xin Lang Cai Jing·2025-08-15 05:39